BioSpace News Archive

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the second quarter of 2021, and provided updates on its ophthalmology pipeline.

Fulgent Genetics, Inc. today announced that it has acquired CSI Laboratories (“CSI”) to expand its presence in somatic molecular diagnostics and cancer testing.

Rocket Pharmaceuticals, Inc. today reports financial results for the quarter ending June 30, 2021 and updates on the Company’s key pipeline developments, business operations, and upcoming milestones.

Atara Biotherapeutics, Inc. today reported financial results for the second quarter 2021, recent business highlights and key catalysts over the next several months.

Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021.

Myomo, Inc. today announced financial results for the three and six months ended June 30, 2021.

Fulgent Genetics, Inc. today announced financial results for its second quarter ended June 30, 2021.

Senseonics Holdings, Inc. today reported financial results for the quarter ended June 30, 2021.

STERIS plc announced financial results for its fiscal 2022 first quarter ended June 30, 2021.

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), today announced that the Japanese Patent Office (“JPO”) issued Japanese Patent No. 2019-189551 Notice of Allowance for the Company’s xB3-IDS fusion proteins.